Biomarin Withdraws Voxzogo Reimbursement Applic...

By HEOR Staff Writer

March 16, 2026

Voxzogo reimbursement Netherlands hangs in limbo after Biomarin's decision on March 12, 2026, to withdraw its application, leaving children with achondroplasia without access despite parental pleas.
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Paving the Way for Digital Health Technologies: NICE’s Bold New Strateg...
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival